Pasar al contenido principal

CORTISTATINA: COMO SUPERAR EL OBSTACULO TRASLACIONAL DEL ACCIDENTE CEREBROVASCULAR ISQUEMICO

PRE2021-100172

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Desarrollar, Atraer y Retener Talento
Subprograma Subprograma Estatal de Formación
Convocatoria Contratos Predoctorales
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel Therapeutic Opportunities for Neurodegenerative Diseases with Mesenchymal Stem Cells: The Focus on Modulating the Blood-Brain Barrier

  • Vargas-Rodríguez, Pablo
  • Cuenca-Martagón, Alejandro
  • Castillo-González, Julia
  • Serrano-Martínez, Ignacio
  • Luque, Raúl M.
  • Delgado, Mario
  • González-Rey, Elena
Neurodegenerative disorders encompass a broad spectrum of profoundly disabling situations that impact millions of individuals globally. While their underlying causes and pathophysiology display considerable diversity and remain incompletely understood, a mounting body of evidence indicates that the disruption of blood-brain barrier (BBB) permeability, resulting in brain damage and neuroinflammation, is a common feature among them. Consequently, targeting the BBB has emerged as an innovative therapeutic strategy for addressing neurological disorders. Within this review, we not only explore the neuroprotective, neurotrophic, and immunomodulatory benefits of mesenchymal stem cells (MSCs) in combating neurodegeneration but also delve into their recent role in modulating the BBB. We will investigate the cellular and molecular mechanisms through which MSC treatment impacts primary age-related neurological conditions like Alzheimer’s disease, Parkinson’s disease, and stroke, as well as immune-mediated diseases such as multiple sclerosis. Our focus will center on how MSCs participate in the modulation of cell transporters, matrix remodeling, stabilization of cell-junction components, and restoration of BBB network integrity in these pathological contexts., This work was supported by the Spanish Ministry of Science and Innovation (PID2020-119638RB-I00 to E.G-R., PhD fellowship FPU17/02616 to J.C-G., and PRE2021-100172 to P.V-R) and Next Generation EU (Investigo—E-14-2023-0079369) to A.C-M., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cortistatin as a novel multimodal therapy for the treatment of Parkinson’s disease

  • Serrano-Martínez, Ignacio
  • Pedreño, Marta
  • Castillo-González, Julia
  • Ferraz-de-Paula, Viviane
  • Vargas-Rodríguez, Pablo
  • Forte-Lago, Irene
  • Caro, Marta
  • Campos-Salinas, Jenny
  • Villadiego, Javier
  • Peñalver, Pablo
  • Morales, Juan Carlos
  • Delgado, Mario
  • González-Rey, Elena
Parkinson’s disease (PD) is a complex disorder characterized by the impairment of the dopaminergic nigrostriatal system. PD has duplicated its global burden in the last few years, becoming the leading neurological disability worldwide. Therefore, there is an urgent need to develop innovative approaches that target multifactorial underlying causes to potentially prevent or limit disease progression. Accumulating evidence suggests that neuroinflammatory responses may play a pivotal role in the neurodegenerative processes that occur during the development of PD. Cortistatin is a neuropeptide that has shown potent anti-inflammatory and immunoregulatory effects in preclinical models of autoimmune and neuroinflammatory disorders. The goal of this study was to explore the therapeutic potential of cortistatin in a well-established preclinical mouse model of PD induced by acute exposure to the neurotoxin 1-methil-4-phenyl1-1,2,3,6-tetrahydropyridine (MPTP). We observed that treatment with cortistatin mitigated the MPTP-induced loss of dopaminergic neurons in the substantia nigra and their connections to the striatum. Consequently, cortistatin administration improved the locomotor activity of animals intoxicated with MPTP. In addition, cortistatin diminished the presence and activation of glial cells in the affected brain regions of MPTP-treated mice, reduced the production of immune mediators, and promoted the expression of neurotrophic factors in the striatum. In an in vitro model of PD, treatment with cortistatin also demonstrated a reduction in the cell death of dopaminergic neurons that were exposed to the neurotoxin. Taken together, these findings suggest that cortistatin could emerge as a promising new therapeutic agent that combines anti-inflammatory and neuroprotective properties to regulate the progression of PD at multiple levels., This research was funded by the grant PROYEXCEL_00867 from the Regional Andalusian Government (to E.G.-R.) and by the MCIN/Spanish Research Agency (AEI)/10.13039/501100011033 grants: PID2020-119638RB-I00 (to E.G.-R.), FPU-program FPU17/02616 (to J.C.-G.), FPI-program PRE2018-084824 (to I.S.-M.) and PRE2021-100172 (to P.V.-R.). Moreover, V.F.-de-P received a postdoctoral fellowship from the Conselho Nacional de Desenvolvimento (Científico e Tecnológico-process 203745/2014-0) from the Brazilian Federal Government., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lack of cortistatin drives neuroimmune and vascular dysfunction in brain ischemia

  • Castillo-González, Julia
  • Vargas-Rodríguez, Pablo
  • Serrano-Martínez, Ignacio
  • Cuenca-Martagón, Alejandro
  • Forte-Lago, Irene
  • Price, Melanie
  • Buscemi, Lara
  • Hirt, Lorenz
  • Ruiz Rodríguez, Jose Luis
  • González-Rey, Elena
RNA-seq data are available in the GEO repository under accession number GSE302342, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302342., [Background] Ischemic stroke remains a leading cause of death and disability, with limited therapies addressing its pathophysiology. Neuroinflammation, blood–brain barrier disruption, and immune dysregulation critically contribute to both acute neuronal injury and chronic functional decline. Elucidating the endogenous factors that govern these processes and understanding the intricate interplay among them is essential for developing effective therapeutic strategies. Cortistatin, a neuropeptide expressed in the nervous and immune systems, exhibits potent immunomodulatory actions, but its role in neuroinflammatory diseases remains unclear., [Methods] In this study, we combined human and murine transcriptomic analyses with a preclinical stroke model in cortistatin-deficient mice to investigate the endogenous and therapeutic roles of cortistatin during the acute (48 h) and subacute (7 days) phases of ischemic stroke., [Results] We demonstrate for the first time that cortistatin deficiency amplified ischemia-induced transcriptional programs, heightening neuroinflammation and glial/neurovascular dysfunction, and worsening neurological outcomes. Interestingly, cortistatin deficiency accelerated aging-associated pathological features, underscoring its essential role in neuroimmune and cerebrovascular homeostasis. Conversely, cortistatin administration improved neuronal survival, mitigated immune dysfunction, and preserved myelin and vascular integrity during both the acute and subacute stages., [Conclusions] These findings provide the first evidence identifying cortistatin as an endogenous neuroimmune regulator in ischemic stroke and a promising multimodal therapeutic agent for improving acute and long-term outcomes., This work was supported by the Spanish Ministry of Economy and Competitiveness (MCIN)/Spanish Research Agency (AEI)/10.13039/501100011033 grants: SAF2017-85602-R and PID2020-119638RB-I00 (to E.G-R.), FPU-program FPU17/02616 and Ramón Areces Foundation postdoctoral fellowship (to J.C-G.), FPI-program PRE2018-084824 (to I.S-M.), PRE2021-100172 (to P.V-R.) and FPU-program FPU23/00152 (to A.C-M); the grant PROYEXCEL_00867 from the Regional Andalusian Government (to E.G.-R.); the Swiss Science Foundation FNS 310030_212233 grant to L.H, Peer reviewed